A detailed history of Strategic Capital Advisers, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Strategic Capital Advisers, Inc. holds 1,846 shares of ABBV stock, worth $332,280. This represents 0.23% of its overall portfolio holdings.

Number of Shares
1,846
Previous 1,840 0.33%
Holding current value
$332,280
Previous $298,000 5.03%
% of portfolio
0.23%
Previous 0.23%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 18, 2022

BUY
$137.62 - $174.96 $825 - $1,049
6 Added 0.33%
1,846 $283,000
Q1 2022

May 05, 2022

BUY
$131.98 - $163.75 $791 - $982
6 Added 0.33%
1,840 $298,000
Q4 2021

Jan 19, 2022

BUY
$107.43 - $135.93 $197,026 - $249,295
1,834 New
1,834 $248,000
Q2 2020

Aug 06, 2020

SELL
$73.37 - $98.18 $217,101 - $290,514
-2,959 Closed
0 $0
Q1 2020

May 12, 2020

BUY
$64.5 - $97.79 $8,385 - $12,712
130 Added 4.6%
2,959 $225,000
Q4 2019

Jan 27, 2020

BUY
$72.13 - $90.25 $2,019 - $2,527
28 Added 1.0%
2,829 $250,000
Q3 2019

Nov 05, 2019

BUY
$62.98 - $75.72 $944 - $1,135
15 Added 0.54%
2,801 $212,000
Q2 2019

Jul 30, 2019

BUY
$65.7 - $83.98 $1,971 - $2,519
30 Added 1.09%
2,786 $203,000
Q1 2019

May 08, 2019

BUY
$77.14 - $90.79 $40,884 - $48,118
530 Added 23.81%
2,756 $222,000
Q4 2018

Feb 14, 2019

BUY
$77.85 - $96.01 $1,868 - $2,304
24 Added 1.09%
2,226 $205,000
Q3 2018

Oct 29, 2018

BUY
$88.91 - $98.84 $1,867 - $2,075
21 Added 0.96%
2,202 $208,000
Q2 2018

Aug 10, 2018

BUY
$89.78 - $106.23 $2,962 - $3,505
33 Added 1.54%
2,181 $212,000
Q4 2017

Feb 14, 2018

BUY
$89.56 - $98.21 $192,374 - $210,955
2,148
2,148 $208,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Strategic Capital Advisers, Inc. Portfolio

Follow Strategic Capital Advisers, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strategic Capital Advisers, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Strategic Capital Advisers, Inc. with notifications on news.